Arrowhead Pharmaceuticals shares are trading higher after the company reported topline results from the Phase 3 PALISADE study of investigational plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome. Also, the company announced that it met all key secondary endpoints.
Portfolio Pulse from Benzinga Newsdesk
Arrowhead Pharmaceuticals shares are trading higher following positive topline results from the Phase 3 PALISADE study of plozasiran in patients with familial chylomicronemia syndrome. The company also met all key secondary endpoints.
June 03, 2024 | 3:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arrowhead Pharmaceuticals shares are trading higher after the company reported positive topline results from the Phase 3 PALISADE study of plozasiran in patients with familial chylomicronemia syndrome. The company also met all key secondary endpoints.
The positive topline results from the Phase 3 PALISADE study and the achievement of all key secondary endpoints are significant milestones for Arrowhead Pharmaceuticals. This news is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100